Short Interest in TransMedics Group, Inc. (NASDAQ:TMDX) Expands By 30.9%

TransMedics Group, Inc. (NASDAQ:TMDX) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 8,430,000 shares, an increase of 30.9% from the October 15th total of 6,440,000 shares. Based on an average trading volume of 1,390,000 shares, the days-to-cover ratio is currently 6.1 days.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of research reports. Oppenheimer dropped their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Robert W. Baird dropped their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Finally, Stephens upped their price objective on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Price Performance

TMDX traded down $7.88 during trading on Friday, hitting $80.48. The company’s stock had a trading volume of 2,305,980 shares, compared to its average volume of 969,652. TransMedics Group has a 12 month low of $63.85 and a 12 month high of $177.37. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of 85.62 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm’s 50 day moving average price is $125.63 and its two-hundred day moving average price is $139.09.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the company earned ($0.12) EPS. The firm’s revenue was up 63.7% compared to the same quarter last year. Sell-side analysts forecast that TransMedics Group will post 1.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. The trade was a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,958 shares of company stock valued at $5,230,528. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently modified their holdings of TMDX. Vaughan Nelson Investment Management L.P. acquired a new stake in TransMedics Group during the 2nd quarter worth $39,862,000. Driehaus Capital Management LLC boosted its position in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the period. Hood River Capital Management LLC acquired a new stake in shares of TransMedics Group during the second quarter worth $18,854,000. Finally, Canada Pension Plan Investment Board bought a new stake in TransMedics Group in the second quarter valued at about $16,086,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.